Key facts
- Brattea’s last known valuation is $422.3M (Feb 2025).
- It has raised $144.3M; the latest was Later Stage VC ($20.6M) in Feb 2025.
- Notable investors include SAIC Capital China, Northern Light Venture Capital, Dalton Venture, CCB International, Shanghai Healthcare Capital — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Brattea
- ·The full record, as it builds
Funding rounds
No funding rounds for Brattea are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Brattea
Developer of hypertension interventional devices designed for medical health. The company has products including renal artery ablation catheter, radiofrequency ablation equipment, and other medical mapping system equipment, which can offer treatment of refractory hypertension, obstructive sleep apnea, kidney disease, heart failure, etc, providing custimers with reliable products.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2013
- Employees
- 19
- Website
- brattea.com/
- Ownership
- Privately Held (backing)
Brattea doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Brattea shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Brattea in its N-PORT filings yet. We sweep new filings monthly.